Case reports in gastroenterology
Cure8 research brief
Why This Matters
The report highlights a rare transient neuro-ophthalmic event occurring shortly after infliximab infusion, which may be important for patients and clinicians using anti-TNF therapy to recognize and evaluate.
Who Should Pay Attention
Adult patients on infliximab/anti-TNF therapy, clinicians prescribing biologics, and caregivers monitoring for neurological or visual symptoms.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
A 32-year-old man in remission on infliximab experienced sudden right temporal visual field loss lasting 15–30 minutes, followed by several hours of blurred vision, mild periorbital pain, and headache about 2 days after an infusion.
Eye exam, brain and orbit MRI/CT with contrast, ECG, and transthoracic echocardiography were unremarkable; symptoms resolved spontaneously. The patient reported a prior transient right-sided limb weakness after earlier infliximab exposure, suggesting a recurrent transient neurological pattern.
The authors emphasize that a single case cannot establish causality. They recommend excluding vascular, inflammatory, demyelinating, and migrainous causes when similar events occur and remaining vigilant for rare transient neurological symptoms in patients receiving anti-TNF agents.
Keep In Mind
Single-case (case report) evidence cannot establish causation. The published content is an abstract-level report; interpretation should be cautious and consider broader safety data and clinician evaluation for alternate causes.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationCase reports in gastroenterology
AuthorsShahbaz A, AlMohtasib S, Sajjadi F +2 more
Study typeJournal article, case reports
Indexed viaEurope PMC
Source typeResearch paper
PublishedJan 1, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Ustekinumab-induced Focal Segmental... : Journal of Nature and Science of Medicine - Ovid
This case suggests ustekinumab — a commonly used biologic for Crohn’s disease — might rarely be associated with kidney injury (FSGS). Patients and clinicians should be aware of new or worsening edema, proteinuria, or...
Palisaded Neutrophilic and Granulomatous Dermatitis in Crohn's Disease under Infliximab Therapy with Concomitant Herpes Zoster Infection: A Case Report.
New or unusual skin lesions in people with Crohn’s disease can signal immune‑related skin disease that may be linked to the underlying IBD, biologic therapy, or recent infections. Recognizing PNGD can prompt appropriate...
Plaque Psoriasis and Crohn’s Disease: Shared Biology, the IL-12/23 Pathway and Clinical Considerations
Psoriasis and Crohn’s disease share immune pathways that affect treatment choices. Some biologics work across both conditions while others (notably IL-17 inhibitors) may be inappropriate for patients with active IBD.